跳至主要内容
临床试验/NCT03721939
NCT03721939已完成不适用

BEnefit of Arterial Preparation by LONGitudinal Scoring Before Paclitaxel Eluting Balloon Angioplasty of the Superficial Femoral and Popliteal Artery

VentureMed Group Inc.1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2018年10月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
Absence of clinically driven target lesion revascularization (CDTLR) at 12 months

研究概览

简要总结

The purpose of the artery preparation concept is to perform regular longitudinal micro-incisions on the inner side of the artery ("scoring") and therefore promote a regular expansion of atheroma by balloon inflation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients ≥ 18-year-old, with symptomatic lower extremity occlusive arterial disease
  • Rutherford class of symptom 2 to 5
  • Atheromatous ≥ 70 % stenosis or occlusion of SFA and/or PA
  • Absence of > 50% residual stenosis of the run-in vessels at the end of procedure
  • Presence of at least one patent (no ≥ 50 % stenosis) run-off tibial or fibular vessel to the foot at the end of procedure
  • De novo or restenotic lesions, including in-stent restenosis
  • Willingness to participate in the study and signature of informed consent

排除标准

  • Renal failure with glomerular filtration rate (GFR) 30 ml/min or below, estimated by the Cockroft-Gault equation.
  • Women who are pregnant, lactating, or planning to become pregnant during the duration of the study
  • Recent artery thrombosis, at risk of distal embolization during percutaneous procedure
  • Previous use of a PCB in the lesion during last 15 months
  • Extremely calcified lesions, defined by calcification involving ³ 270° of the artery circumference over ³ 15 cm.
  • Sub-intimal recanalization
  • Tortuous contra-lateral femoral access with difficult cross-over
  • Previous or planned surgery of the target lesion
  • High risk of bleeding
  • Contra-indication to dual antiplatelet therapy for one month, and/or to single antiplatelet therapy for 1 year
  • Allergy to aspirin, clopidogrel or heparin
  • Life expectancy less than one year

结局指标

主要结局

Absence of clinically driven target lesion revascularization (CDTLR) at 12 months

时间窗: 12 months

Occurrence of death from cardiovascular origin

时间窗: 12 months

Occurrence of major amputation of target limb

时间窗: 12 months

次要结局

  • Change in ankle brachial index (ABI)(3 and 12 months)
  • Proportion of luminal gain(Average of 2 hours)
  • Technical success of the scoring procedure(Average of 2 hours)
  • Absence of CDTLR(3 months)
  • Absence of major amputation(3 and 12 months)
  • Change in Rutherford class of symptom(3 and 12 Months)
  • Primary patency of the treated lesion (defined by PSVR ≤ 2.5 at duplex scan)(3 and 12 months)
  • Occurrence of dissection(Average of 2 hours)
  • Proportion of stent implantation(Average of 2 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验